Mar 10, 2021 / 04:00PM GMT
Yona Levites -
Welcome to the live discussion of the -- symposium, Abeta-targeting therapies in AD #1. So my name is Yona Levites. I'm from Center for Translational Research in Neurodegenerative Diseases in University of Florida. And my co-moderator is Dr. Luka Kulic, and he will introduce himself, and then all the members of our discussion will introduce themselves.
Luka Kulic -
Thank you very much, Yona. Yes, I'm Luka Kulic. I'm a neurologist by training and am a medical director, working at Roche Pharma Research and Early Development in Basel, and leading several Alzheimer's disease programs approach. Then I'll hand over to Laura.
Laura Nisenbaum -
Thank you. My name is Laura Nisenbaum. It's a pleasure for me to be part of this session. I really appreciate the invitation. I lead the Diagnostic Pathway Group at Biogen and am also responsible for the biomarker strategy for aducanumab. Thanks.
Luka Kulic -
Michelle? Sorry.
Michelle Gee -
Okay. I'm Michelle Gee, and I'm
Biogen Inc Live Discussion of Cerebrospinal Fluid Biomarker Concordance with Amyloid PET in EMERGE and ENGAGE at AD/PD Transcript
Mar 10, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers